This was observed in the CCTG CO.26 trial, in which patients with refractory pMMR/MSS CRC were randomized to receive anti-PD-L1 (Durvalumab) and anti-CTLA-4 (Tremelimumab) monoclonal antibodies (mAbs) versus best supportive care. This evidence concerns the gene CD274 and colorectal carcinoma.